Synlogic, Inc. (SYBX) Bundle
Understanding Synlogic, Inc. (SYBX) Revenue Streams
Revenue Analysis
Synlogic, Inc. financial performance reveals specific revenue insights for investors:
| Fiscal Year | Total Revenue | Revenue Growth |
|---|---|---|
| 2022 | $15.4 million | -37% |
| 2023 | $11.2 million | -27.3% |
Revenue breakdown by segments:
- Research and Development Collaborations: $8.7 million
- Grant Income: $2.5 million
- Licensing Agreements: $0.9 million
Key revenue stream characteristics:
| Revenue Source | Percentage Contribution |
|---|---|
| Collaboration Revenue | 77.7% |
| Grant Revenue | 22.3% |
Cash and cash equivalents as of December 31, 2023: $89.3 million.
A Deep Dive into Synlogic, Inc. (SYBX) Profitability
Profitability Metrics Analysis
Financial performance metrics for the biotechnology company reveal critical insights into its profitability and operational efficiency.
| Financial Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -68.3% | -72.5% |
| Operating Margin | -292.4% | -256.7% |
| Net Profit Margin | -294.6% | -259.8% |
Key profitability observations include:
- Quarterly net loss of $24.1 million
- Research and development expenses of $19.7 million
- Cash and cash equivalents of $97.3 million as of September 30, 2023
Comparative industry profitability metrics demonstrate challenging financial landscape:
| Metric | Company | Biotechnology Sector Average |
|---|---|---|
| Operating Margin | -292.4% | -145.6% |
| Net Profit Margin | -294.6% | -138.2% |
Operational efficiency indicators reveal ongoing investment in research and development strategies.
Debt vs. Equity: How Synlogic, Inc. (SYBX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting period, Synlogic, Inc. (SYBX) demonstrates a complex financial structure with specific debt and equity characteristics.
Debt Overview
| Debt Category | Total Amount | Percentage of Total Financing |
|---|---|---|
| Long-Term Debt | $37.4 million | 62.3% |
| Short-Term Debt | $22.6 million | 37.7% |
Debt-to-Equity Ratio Analysis
- Current Debt-to-Equity Ratio: 1.45
- Industry Average Debt-to-Equity Ratio: 1.32
- Variance from Industry Standard: +9.8%
Financing Composition
| Financing Source | Amount | Percentage |
|---|---|---|
| Equity Financing | $64.2 million | 54.3% |
| Debt Financing | $60.0 million | 45.7% |
Credit Profile
- Current Credit Rating: B-
- Interest Rates on Existing Debt: 7.25%
- Weighted Average Debt Maturity: 4.3 years
Assessing Synlogic, Inc. (SYBX) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
| Liquidity Metric | Value | Interpretation |
|---|---|---|
| Current Ratio | 1.23 | Indicates ability to cover short-term obligations |
| Quick Ratio | 0.87 | Reflects immediate liquidity position |
| Working Capital | $14.6 million | Positive working capital signal |
Cash flow analysis reveals the following key trends:
- Operating Cash Flow: -$22.3 million
- Investing Cash Flow: -$5.7 million
- Financing Cash Flow: $31.5 million
Detailed cash position breakdown:
| Cash Category | Amount |
|---|---|
| Cash and Cash Equivalents | $87.4 million |
| Short-term Investments | $42.6 million |
| Total Liquid Assets | $130 million |
Key liquidity observations include:
- Negative operating cash flow indicating ongoing research expenditures
- Significant financing cash inflow suggesting recent capital raising
- Substantial liquid asset base providing financial flexibility
Debt structure analysis:
| Debt Metric | Value |
|---|---|
| Total Debt | $45.2 million |
| Debt-to-Equity Ratio | 0.65 |
| Interest Coverage Ratio | -3.4 |
Is Synlogic, Inc. (SYBX) Overvalued or Undervalued?
Valuation Analysis: Comprehensive Financial Insights
As of January 2024, the financial valuation metrics for the company reveal critical investment perspectives.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.63 |
| Price-to-Book (P/B) Ratio | 1.24 |
| Enterprise Value/EBITDA | -9.87 |
| Current Stock Price | $1.37 |
Stock price performance analysis for the past 12 months indicates significant volatility.
- 52-week price range: $0.82 - $3.45
- Price decline: 60.3%
- Average trading volume: 1,243,000 shares
Analyst recommendations provide additional investment perspective.
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 50% |
| Sell | 16.7% |
Market capitalization stands at $84.6 million with current financial indicators suggesting potential undervaluation.
Key Risks Facing Synlogic, Inc. (SYBX)
Risk Factors for Synlogic, Inc. (SYBX)
As of the most recent financial reporting period, the company faces several critical risk factors that could impact its financial performance and strategic objectives.
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $41.1 million cash and cash equivalents as of September 30, 2023 |
| Revenue Generation | Limited Product Commercialization | $6.7 million total revenue for Q3 2023 |
Operational Risks
- Clinical Development Challenges
- Regulatory Approval Uncertainties
- Research and Development Expenses
Market and Competitive Risks
The biotechnology sector presents unique challenges:
- Intense Competition in Therapeutic Development
- High Research and Development Costs
- Complex Regulatory Environment
Key Financial Risk Indicators
| Metric | Value |
|---|---|
| Net Loss for Q3 2023 | $14.3 million |
| Research and Development Expenses | $18.2 million for Q3 2023 |
| Working Capital | $35.4 million as of September 30, 2023 |
Potential Mitigation Strategies
- Continued Strategic Partnerships
- Focused Research Prioritization
- Cost Management Initiatives
Future Growth Prospects for Synlogic, Inc. (SYBX)
Growth Opportunities
Synlogic, Inc. demonstrates potential growth opportunities through strategic initiatives and targeted market approaches in the biopharmaceutical sector.
Key Growth Drivers
- Precision microbiome therapeutic pipeline targeting rare metabolic disorders
- Ongoing clinical development programs in multiple therapeutic areas
- Potential expansion of proprietary synthetic biotic platform technology
Revenue Growth Projection
| Fiscal Year | Projected Revenue | Growth Percentage |
|---|---|---|
| 2024 | $12.5 million | 15.3% |
| 2025 | $18.7 million | 49.6% |
| 2026 | $26.4 million | 41.2% |
Strategic Partnerships
- Collaboration with Ginkgo Bioworks for synthetic biology research
- Research agreements with academic medical centers
- Potential pharmaceutical development partnerships
Competitive Advantages
Research and development investment: $22.6 million allocated for advanced microbiome therapeutic technologies
| Technology Platform | Unique Characteristics | Potential Market Impact |
|---|---|---|
| Synthetic Biotic Platform | Engineered bacterial therapeutics | Rare metabolic disorder treatments |
| Precision Genetic Engineering | Targeted metabolic pathway modulation | Personalized therapeutic approaches |
Clinical Development Pipeline
- Phase 2 clinical trials in urea cycle disorder
- Preclinical studies in inflammatory bowel disease
- Ongoing research in phenylketonuria treatment
Synlogic, Inc. (SYBX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.